Professional Documents
Culture Documents
Vancomycin
David R. McNamara, MD, and James M. Steckelberg, MD
Despite use that spans more than four decades, vanco- The efficacy of vancomycin in bacterial killing prima-
mycin remains one of the most important antibiotics in rily correlates with the duration of exposure of suscep-
orthopaedic practice. It has increased in importance in tible bacteria to a sufficient concentration of the drug. This
the last decade because of the growing resistance of many is expressed as the ratio of the area under the plasma con-
gram-positive bacteria to β-lactam antibiotics, such as pen- centration curve to minimal inhibitory concentration
icillins and cephalosporins. These gram-positive bacte- (AUC:MIC). Antibacterial effects that persist after drug
Downloaded from http://journals.lww.com/jaaos by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC4/OAVpDDa8K2+Ya6H515kE= on 06/05/2021
ria, especially Staphylococcus aureus and coagulase- exposure (postantibiotic effect) also contribute to its an-
negative staphylococci, cause a large proportion of the tibacterial effect.2 The goal of vancomycin dosing is to
infections encountered in orthopaedic surgical practice, optimize exposure of susceptible bacteria to a sufficient
especially those involving implanted hardware. concentration of the drug while avoiding drug toxicity.
Pharmacokinetics
Vancomycin is poorly absorbed from the gastrointesti-
Dr. McNamara is Instructor of Medicine, Mayo Clinic College of Medi-
nal tract and requires IV administration for the treatment cine, Rochester, MN. Dr. Steckelberg is Professor of Medicine, Mayo Clinic
of systemic or orthopaedic infections. (The only role for College of Medicine.
oral vancomycin is treatment of Clostridium difficile coli-
tis.) After an IV dose, the first distributive phase has a None of the following authors or the departments with which they are af-
filiated has received anything of value from or owns stock in a commercial
half-life of approximately 0.4 hours; the second distrib-
company or institution related directly or indirectly to the subject of this
utive phase half-life is approximately 1.6 hours. Clear- article: Dr. McNamara and Dr. Steckelberg.
ance is primarily through renal glomerular filtration, with
hepatic metabolism only a minor contributor to drug elim- Reprint requests: Dr. Steckelberg, Mayo Clinic College of Medicine, 200 First
ination. In the presence of normal renal function, the elim- Street SW, Rochester, MN 55905.
ination half-life is approximately 6 hours. Within 24 hours,
Copyright 2005 by the American Academy of Orthopaedic Surgeons.
70% to 90% of the dose is excreted unchanged in the
urine.1 Drug dosing requires significant adjustment for J Am Acad Orthop Surg 2005;13:89-92
both patient size and renal function.
bone-to-serum concentration ratio is less clear because involves a pruritic, erythematous rash on the upper trunk,
of differences in methods between studies, limitations in neck, and face associated with rapid vancomycin infu-
extrapolating data from animal models using S aureus as sion causing histamine release. Vancomycin should be
the infecting agent, and the lack of long-term follow-up infused at a rate of 1,000 mg over 60 minutes, with larger
inherent in experimental animal models.11 doses taking proportionately longer to infuse. Red man
In addition to systemic parenteral vancomycin ther- syndrome can be ameliorated with a slower rate of in-
apy, local delivery of antibiotics via impregnated poly- fusion and antihistamine premedication.15 Peripheral vein
methylmethacrylate (PMMA) beads is commonly used phlebitis with vancomycin therapy is common and can
in the treatment of chronic osteomyelitis or prosthetic joint be avoided by infusion via a central venous catheter, such
infection. The heat stability of vancomycin, in contrast as a peripherally inserted central catheter (PICC), when
to that of β-lactam antibiotics (which are degraded dur- therapy is anticipated to last longer than 10 to 14 days.
ing the PMMA polymerization process), makes it a use- More serious adverse effects include ototoxicity and
ful drug for this application.10 nephrotoxicity. Cranial eighth nerve damage may result
Vancomycin-impregnated PMMA beads have not been in permanent equilibrium or hearing loss. Vestibular tox-
approved by the FDA and are not commercially avail- icity can be particularly troublesome for patients who al-
able in the United States. For use in the treatment of in- ready have gait difficulty as a result of orthopaedic prob-
fected bone as antibiotic-impregnated cement beads or lems. Concomitant aminoglycoside use has been linked
spacer, in which structural strength of the cement is not with increased risk of both ototoxicity and nephrotox-
of primary importance, up to 4 g vancomycin into 40 g icity.16 Other potentially serious complications of vanco-
PMMA cement can be used, often in combination with mycin therapy include hypersensitivity rash, reversible
an aminoglycoside antibiotic. Increasing concentrations neutropenia, and, rarely, drug fever. Vancomycin does not
of vancomycin may have a negative effect on the mechan- significantly interact with other medications, although
ical strength and stability of the cement. For use in which concomitant administration of other potentially nephro-
the structural integrity of the cement is important (eg, toxic or ototoxic drugs may increase the risk of these com-
prosthesis fixation), only 0.5 to 1 g of powdered antibi- plications.
otic per 40 g of PMMA cement is recommended to avoid
weakening the bone cement.5 Also, the use of vancomycin-
impregnated bone cement should be avoided in prophy- Dosage and Cost
lactic applications and limited to the treatment of estab-
lished infection.5 An in vitro evaluation of drug release Dosing nomograms use both estimated creatinine clear-
from PMMA beads in a continuous flow chamber showed ance and body weight to determine a dose and dosing
that vancomycin-impregnated PMMA beads had a sim- frequency (Table 1, available at http://www5.aaos.org/
ilar percentage of antibiotic release to that of gentamicin- jaaos/pdf/v13n2a1t1.pdf). Empiric nomograms may not
and tobramycin-impregnated PMMA beads.12 accurately guide dosing for patients with changing re-
Various commercially available PMMA products may nal function, anuria, or dialysis who will require serum
differ in their vancomycin elution characteristics. The in drug concentration monitoring to adjust doses. The av-
vivo significance of in vitro findings in studies compar- erage wholesale price of daily doses of vancomycin com-
ing different PMMA products is unclear. In addition, elu- pared with other antibacterials commonly used in ortho-
tion characteristics for vancomycin may change in com- paedic surgical practice is shown in Table 2.
bination with other antibiotics. One study found the in Patients with end-stage renal failure on dialysis have
vitro elution of vancomycin in combination with tobra- often been dosed with once-weekly vancomycin because
mycin via Palacos R cement (Biomet, Warsaw, IN) to be of low clearance with traditional dialysis membranes.
greater than that of CMW 1 or CMW 3 cement (DePuy, Newer dialysis techniques incorporating high-flux mem-
Warsaw, IN).13 Another study evaluating the in vitro elu- branes, in addition to continuous renal replacement ther-
tion of vancomycin in Palacos R, CMW, and Simplex P apies used in hospitalized patients, clear vancomycin
cement (Stryker, Kalamazoo, MI) found that the addition more rapidly and require more frequent dosing and of-
of imipenem-cilastatin significantly (P < 0.5) increased ten larger vancomycin doses. Input from infectious dis-
the elution of vancomycin from all three cements.14 ease specialists and health-system pharmacists with ex-
pertise in therapeutic drug monitoring and antibiotic
dosing during renal replacement therapy is often valu-
Drug Interactions and Adverse Effects able in achieving accurate dosing of vancomycin in re-
nal impairment.
Common adverse effects include infusion-related pruri- Measurement of vancomycin concentration in serum
tis and erythema as well as phlebitis. Red man syndrome is often performed to guide dosing, especially in patients
References
1. Wilhelm MP, Estes L: Symposium on antimicrobial agents: XII. Farinotti R: Penetration of vancomycin in uninfected sternal
Vancomycin. Mayo Clin Proc 1999;74:928-935. bone. Antimicrob Agents Chemother 1992;36:2539-2541.
2. Craig WA: Basic pharmacodynamics of antibacterials with clin- 10. Mader JT, Shirtliff ME, Bergquist SC, Calhoun J: Antimicrobial
ical application to the use of beta-lactams, glycopeptides, and treatment of chronic osteomyelitis. Clin Orthop 1999;360:47-65.
linezolid. Infect Dis Clin North Am 2003;17:479-501. 11. Darley ES, MacGowan AP: Antibiotic treatment of gram-
3. Murray BE: Vancomycin-resistant enterococcal infections. N positive bone and joint infections. J Antimicrob Chemother 2004;
Engl J Med 2000;342:710-721. 53:928-935.
4. Recommendations for preventing the spread of vancomycin re- 12. Perry AC, Rouse MS, Khaliq Y, et al: Antimicrobial release ki-
sistance. Recommendations of the Hospital Infection Control netics from polymethylmethacrylate in a novel continuous flow
Practices Advisory Committee (HICPAC). MMWR Recomm Rep chamber. Clin Orthop 2002;403:49-53.
1995:44:1-13. 13. Penner MJ, Duncan CP, Masri BA: The in vitro elution charac-
5. Hanssen AD, Osmon DR: The use of prophylactic antimicrobial teristics of antibiotic-loaded CMW and Palacos-R bone cements.
agents during and after hip arthroplasty. Clin Orthop 1999;369: J Arthroplasty 1999;14:209-214.
124-138. 14. Cerretani D, Giorgi G, Fornara P, et al: The in vitro elution char-
6. Li JT, Markus PJ, Osmon DR, Estes L, Gosselin VA, Hanssen AD: acteristics of vancomycin combined with imipenem-cilastatin
Reduction of vancomycin use in orthopedic patients with a his- in acrylic bone-cements: A pharmacokinetic study. J Arthroplasty
tory of antibiotic allergy. Mayo Clin Proc 2000;75:902-906. 2002;17:619-626.
7. Berbari EF, Osmon DR, Steckelberg JM: Osteomyelitis and in- 15. Sahai J, Healy DP, Garris R, Berry A, Polk RE: Influence of an-
fectious arthritis, in Baddour LM, Gorbach SL (eds): Therapy of tihistamine pretreatment on vancomycin-induced red-man syn-
Infectious Diseases. Philadelphia, PA: WB Saunders, 2003, pp drome. J Infect Dis 1989;160:876-881.
331-342. 16. Sorrell TC, Collignon PJ: A prospective study of adverse reac-
8. Graziani AL, Lawson LA, Gibson GA, Steinberg MA, Mac- tions associated with vancomycin therapy. J Antimicrob
Gregor RR: Vancomycin concentrations in infected and nonin- Chemother 1985;16:235-241.
fected human bone. Antimicrob Agents Chemother 1988;32: 17. Zimmerman AE, Katona BG, Plaisance KI: Association of van-
1320-1322. comycin serum concentrations with outcomes in patients with
9. Massias L, Dubois C, de Lentdecker P, Brodaty O, Fischler M, gram-positive bacteremia. Pharmacotherapy 1995;15:85-91.